JO3319B1 - مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين - Google Patents

مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين

Info

Publication number
JO3319B1
JO3319B1 JOP/2008/0231A JOP20080231A JO3319B1 JO 3319 B1 JO3319 B1 JO 3319B1 JO P20080231 A JOP20080231 A JO P20080231A JO 3319 B1 JO3319 B1 JO 3319B1
Authority
JO
Jordan
Prior art keywords
pyrazolo
pyridines
imidazolyl
compounds
ccr1
Prior art date
Application number
JOP/2008/0231A
Other languages
English (en)
Inventor
M K Pennell Andrew
Zhang Penglie
Li Lianfa
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of JO3319B1 publication Critical patent/JO3319B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع بتوفير مركبات تعمل كمضادات قوية لمستقبل CCR1، ولها نشاط مضاد للالتهابات في الكائن الحي، وتتمثل تلك المركبات في مشتقات 3-ايميدازوليل- بيرازولو [3، 4- b] بيريدين وتكوين مفيدة في تركيات صيدلانية، وطرق لعلاج مرض يتسبب فيه CCR1، وكعينات مقارنة في اختبارات تحديد مضادات CCR1 تنافسية.
JOP/2008/0231A 2007-05-22 2008-05-22 مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين JO3319B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93294807P 2007-05-22 2007-05-22

Publications (1)

Publication Number Publication Date
JO3319B1 true JO3319B1 (ar) 2019-03-13

Family

ID=40075474

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2008/0231A JO3319B1 (ar) 2007-05-22 2008-05-22 مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين

Country Status (26)

Country Link
US (4) US7629344B2 (ar)
EP (1) EP2155712B1 (ar)
JP (1) JP5457338B2 (ar)
KR (1) KR101534661B1 (ar)
CN (1) CN101743238B (ar)
AR (2) AR066701A1 (ar)
AU (1) AU2008256862B2 (ar)
BR (1) BRPI0811849A8 (ar)
CA (1) CA2687625C (ar)
CL (1) CL2008001493A1 (ar)
CO (1) CO6241152A2 (ar)
DK (1) DK2155712T3 (ar)
EA (1) EA015529B1 (ar)
ES (1) ES2600477T3 (ar)
HU (1) HUE032273T2 (ar)
IL (1) IL202248A (ar)
JO (1) JO3319B1 (ar)
MA (1) MA31442B1 (ar)
MX (1) MX2009012567A (ar)
NZ (1) NZ581405A (ar)
PE (1) PE20090293A1 (ar)
PL (1) PL2155712T3 (ar)
PT (1) PT2155712T (ar)
TW (1) TWI418353B (ar)
UA (1) UA99619C2 (ar)
WO (1) WO2008147815A1 (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
CA2657347C (en) 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
DK2155712T3 (en) * 2007-05-22 2016-12-19 Chemocentryx Inc 3- (imidazolyl) pyrazolo [3,4-b] pyridines
JP5654467B2 (ja) 2008-09-11 2015-01-14 ケモセントリックス，インコーポレイティド ４−アミノ−３−（イミダゾリル）−ピラゾロ［３，４−ｄ］ピリミジン
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
DK2888261T3 (en) * 2012-08-27 2018-07-30 Chemocentryx Inc Antagonists of chemokine receptors
AU2013355054B2 (en) 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
US20170195506A1 (en) * 2015-12-30 2017-07-06 Kabushiki Kaisha Toshiba Image forming apparatus forming location free print system and print job retrieval method by the same
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
CN114555080B (zh) 2019-10-16 2025-10-10 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯胺
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US715746A (en) * 1902-02-25 1902-12-16 Nat Tube Co Apparatus for handling tube-plates.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
AU517350B2 (en) * 1977-10-26 1981-07-23 Wellcome Foundation Limited, The Imidazoline derivatives
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4927942A (en) * 1988-12-15 1990-05-22 Texaco Chemical Co. Method for the preparation of imidazoles
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
CA2049973C (en) 1990-02-28 2002-12-24 Rodney G. Wolff Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
BRPI0612112A8 (pt) * 2005-06-22 2017-12-26 Chemocentryx Inc composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
KR200434921Y1 (ko) * 2006-07-10 2007-01-02 서용석 야외용 간이 화장실
DK2155712T3 (en) * 2007-05-22 2016-12-19 Chemocentryx Inc 3- (imidazolyl) pyrazolo [3,4-b] pyridines

Also Published As

Publication number Publication date
AU2008256862A8 (en) 2009-12-24
AR110128A2 (es) 2019-02-27
EP2155712A1 (en) 2010-02-24
CA2687625A1 (en) 2008-12-04
BRPI0811849A2 (pt) 2014-11-18
NZ581405A (en) 2011-06-30
AU2008256862B2 (en) 2013-01-31
AU2008256862A1 (en) 2008-12-04
JP5457338B2 (ja) 2014-04-02
PT2155712T (pt) 2016-12-13
UA99619C2 (en) 2012-09-10
US20130184289A1 (en) 2013-07-18
WO2008147815A1 (en) 2008-12-04
IL202248A0 (en) 2010-06-16
US20120010214A1 (en) 2012-01-12
KR101534661B1 (ko) 2015-07-09
PL2155712T3 (pl) 2017-02-28
CN101743238A (zh) 2010-06-16
TWI418353B (zh) 2013-12-11
EP2155712B1 (en) 2016-09-07
US20100173911A1 (en) 2010-07-08
CN101743238B (zh) 2014-04-30
CL2008001493A1 (es) 2008-08-29
AR066701A1 (es) 2009-09-09
HK1141524A1 (zh) 2010-11-12
BRPI0811849A8 (pt) 2019-01-15
PE20090293A1 (es) 2009-04-04
US7960388B2 (en) 2011-06-14
TW200906402A (en) 2009-02-16
CA2687625C (en) 2015-12-22
US20080300257A1 (en) 2008-12-04
ES2600477T3 (es) 2017-02-09
IL202248A (en) 2015-04-30
EA015529B1 (ru) 2011-08-30
HUE032273T2 (en) 2017-09-28
DK2155712T3 (en) 2016-12-19
JP2010528038A (ja) 2010-08-19
KR20100022998A (ko) 2010-03-03
MX2009012567A (es) 2010-02-17
US7629344B2 (en) 2009-12-08
US8481545B2 (en) 2013-07-09
EA200901572A1 (ru) 2010-04-30
CO6241152A2 (es) 2011-01-20
MA31442B1 (fr) 2010-06-01
EP2155712A4 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
JO3319B1 (ar) مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين
EA017278B9 (ru) Соединения азаиндазола и способы применения
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
WO2007073432A3 (en) Piperidine derivatives and methods of use
EP2155203A4 (en) Azaindazole compounds and methods of use
WO2007034282A3 (en) Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
MXPA04012393A (es) Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
PL2175859T3 (pl) Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
MX2015007051A (es) Diazol lactamas.
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
ZA200710611B (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2014100735A3 (en) Diazole amides
WO2012040048A3 (en) Triazolopyrazinones as p2x7 receptor antagonists
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
IL179612A (en) Benzimidazolone carboxylic acid derivatives, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments for the treatment of conditions mediated by 5-ht4 receptor activity
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2007146602A8 (en) Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
WO2007034278A3 (en) Fused imidazole derivatives as c3a receptor antagonists
WO2006037482A3 (en) Compositions and methods for treating cognitive disorders